Skip to main content
Michal Mrug, MD, Nephrology, Birmingham, AL

MichalMrugMD

Nephrology • Birmingham, AL

Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Dr. Mrug is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Mrug's full profile

Already have an account?

  • Office

    1717 6th Ave S
    Birmingham, AL 35233
    Phone+1 800-822-8816
    Fax+1 205-933-4497

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Nephrology, 2002 - 2004
  • USA Health
    USA HealthResidency, Internal Medicine, 1999 - 2002
  • Karlovy University FOM
    Karlovy University FOMClass of 1995

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2002 - 2025
  • Nephrology
    American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Publications & Presentations

PubMed

Journal Articles

  • A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan  
    Ronald D Perrone, Anjay Rastogi, Terry Watnick, Arlene B Chapman, Michal Mrug, Vicente E Torres, Fouad T Chebib, Neera K Dahl, Peter C Harris, Journal of the American Society of Nephrology

Authored Content

  • Baseline Total Kidney Volume and the Rate of Kidney Growth Are Associated with Chronic Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseDecember 2017

Press Mentions

  • Otsuka’s JYNARQUE™ (Tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Otsuka’s JYNARQUE™ (Tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 24th, 2018

Grant Support

  • Role of complement in injury-induced cystogenesis among carriers of a single ADPKD gene defectBIRMINGHAM VA MEDICAL CENTER2024–2028
  • Role of complement in injury-induced cystogenesis among carriers of a single ADPKD gene defectBIRMINGHAM VA MEDICAL CENTER2024–2028

Dr. Michal Mrug, Dr. Michal Mrug, MD, Dr. M Mrug